Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease

PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD). To employ voxel-based analysis method to identify brain regions with significant increases in [(11)C]PIB up...

Full description

Saved in:
Bibliographic Details
Published inNeurology Vol. 67; no. 9; p. 1575
Main Authors Kemppainen, N M, Aalto, S, Wilson, I A, Någren, K, Helin, S, Brück, A, Oikonen, V, Kailajärvi, M, Scheinin, M, Viitanen, M, Parkkola, R, Rinne, J O
Format Journal Article
LanguageEnglish
Published United States 14.11.2006
Subjects
Online AccessGet more information
ISSN1526-632X
DOI10.1212/01.wnl.0000240117.55680.0a

Cover

Loading…
Abstract PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD). To employ voxel-based analysis method to identify brain regions with significant increases in [(11)C]PIB uptake in AD vs healthy control subjects, indicative of increased amyloid accumulation in these regions. We studied 17 patients with AD and 11 control subjects with PET using [(11)C]PIB as tracer. Parametric images were computed by calculating a region-to-cerebellum ratio over 60 to 90 minutes in each voxel. Group differences in [(11)C]PIB uptake were analyzed with statistical parametric mapping (SPM) and automated region-of-interest (ROI) analysis. SPM showed increased uptake (p < 0.001) in the frontal, parietal, and lateral temporal cortices as well as in the posterior cingulate and the striatum. No significant differences in uptake were found in the primary sensory and motor cortices, primary visual cortex, thalamus, and medial temporal lobe. These results were supported by automated ROI analysis, with most prominent increases in AD subjects in the frontal cortex ([(11)C]PIB uptake 163% of the control mean) and posterior cingulate (146%) followed by the parietal (146%) and temporal (145%) cortices and striatum (133%), as well as small increases in the occipital cortex (117%) and thalamus (115%). Voxel-based analysis revealed widespread distribution of increased [(11)C]PIB uptake in Alzheimer disease (AD). These findings are in accordance with the distribution and phases of amyloid pathology in AD, previously documented in postmortem studies.
AbstractList PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD). To employ voxel-based analysis method to identify brain regions with significant increases in [(11)C]PIB uptake in AD vs healthy control subjects, indicative of increased amyloid accumulation in these regions. We studied 17 patients with AD and 11 control subjects with PET using [(11)C]PIB as tracer. Parametric images were computed by calculating a region-to-cerebellum ratio over 60 to 90 minutes in each voxel. Group differences in [(11)C]PIB uptake were analyzed with statistical parametric mapping (SPM) and automated region-of-interest (ROI) analysis. SPM showed increased uptake (p < 0.001) in the frontal, parietal, and lateral temporal cortices as well as in the posterior cingulate and the striatum. No significant differences in uptake were found in the primary sensory and motor cortices, primary visual cortex, thalamus, and medial temporal lobe. These results were supported by automated ROI analysis, with most prominent increases in AD subjects in the frontal cortex ([(11)C]PIB uptake 163% of the control mean) and posterior cingulate (146%) followed by the parietal (146%) and temporal (145%) cortices and striatum (133%), as well as small increases in the occipital cortex (117%) and thalamus (115%). Voxel-based analysis revealed widespread distribution of increased [(11)C]PIB uptake in Alzheimer disease (AD). These findings are in accordance with the distribution and phases of amyloid pathology in AD, previously documented in postmortem studies.
Author Aalto, S
Helin, S
Brück, A
Viitanen, M
Oikonen, V
Wilson, I A
Kailajärvi, M
Scheinin, M
Rinne, J O
Parkkola, R
Kemppainen, N M
Någren, K
Author_xml – sequence: 1
  givenname: N M
  surname: Kemppainen
  fullname: Kemppainen, N M
  organization: Turku PET Centre, University of Turku, Finland
– sequence: 2
  givenname: S
  surname: Aalto
  fullname: Aalto, S
– sequence: 3
  givenname: I A
  surname: Wilson
  fullname: Wilson, I A
– sequence: 4
  givenname: K
  surname: Någren
  fullname: Någren, K
– sequence: 5
  givenname: S
  surname: Helin
  fullname: Helin, S
– sequence: 6
  givenname: A
  surname: Brück
  fullname: Brück, A
– sequence: 7
  givenname: V
  surname: Oikonen
  fullname: Oikonen, V
– sequence: 8
  givenname: M
  surname: Kailajärvi
  fullname: Kailajärvi, M
– sequence: 9
  givenname: M
  surname: Scheinin
  fullname: Scheinin, M
– sequence: 10
  givenname: M
  surname: Viitanen
  fullname: Viitanen, M
– sequence: 11
  givenname: R
  surname: Parkkola
  fullname: Parkkola, R
– sequence: 12
  givenname: J O
  surname: Rinne
  fullname: Rinne, J O
BackLink https://www.ncbi.nlm.nih.gov/pubmed/16971697$$D View this record in MEDLINE/PubMed
BookMark eNo1j11LwzAYhYMo7kP_ggTvW983bZrsco6pg8F2MUUQGWnzRqNpO5YNrb_eiXrgcOC5eOAM2HHTNsTYJUKKAsUVYPrRhBQOETkgqlTKQkMK5oj1UYoiKTLx2GODGN8ADkCNTlkPi5H6aZ8tHtpPCklpIlluGhO66CNvHV9OV9zUXWi95cG_mMbyJ8TJ83J2zfebnXkn7hs-Dl-v5GvacusjHSRn7MSZEOn8b4fs_ma6mtwl88XtbDKeJ1UucZegzTNblZXSUIhcWSXJGlGBBk2EugSps8LpEl1mNbhKOZVrSSRt5qQdkRiyi1_vZl_WZNebra_Ntlv_PxPfrYVSQw
CitedBy_id crossref_primary_10_3233_JAD_180939
crossref_primary_10_3389_fnagi_2019_00084
crossref_primary_10_1212_WNL_0b013e318225118e
crossref_primary_10_1016_j_nicl_2019_102097
crossref_primary_10_1212_WNL_0b013e318212015e
crossref_primary_10_1016_j_jalz_2008_04_005
crossref_primary_10_1159_000109754
crossref_primary_10_1021_jacs_7b05937
crossref_primary_10_2967_jnumed_112_110163
crossref_primary_10_1016_j_neurobiolaging_2011_09_006
crossref_primary_10_1016_j_neuropsychologia_2008_03_020
crossref_primary_10_1080_21553769_2015_1044129
crossref_primary_10_1212_WNL_0000000000004827
crossref_primary_10_4061_2011_759780
crossref_primary_10_1016_j_neuroimage_2008_07_053
crossref_primary_10_1073_pnas_0914141107
crossref_primary_10_1097_JGP_0b013e3181c65821
crossref_primary_10_1007_s00401_019_01965_6
crossref_primary_10_1093_brain_awr130
crossref_primary_10_2967_jnumed_108_057984
crossref_primary_10_1007_s11065_009_9118_x
crossref_primary_10_1093_brain_awq310
crossref_primary_10_2967_jnumed_111_095927
crossref_primary_10_1002_acn3_51238
crossref_primary_10_3389_fnagi_2022_788567
crossref_primary_10_1097_RLU_0000000000000666
crossref_primary_10_3389_fnagi_2021_614809
crossref_primary_10_1016_j_nicl_2013_05_008
crossref_primary_10_1007_s00259_013_2562_0
crossref_primary_10_1080_13825585_2019_1628916
crossref_primary_10_2967_jnumed_107_049619
crossref_primary_10_1093_brain_awt142
crossref_primary_10_1213_01_ane_0000287658_14763_13
crossref_primary_10_1007_s00415_018_9118_y
crossref_primary_10_1097_WCO_0b013e3281a47744
crossref_primary_10_2147_NDT_S268504
crossref_primary_10_1093_brain_awn320
crossref_primary_10_2217_nmt_12_12
crossref_primary_10_1007_s00259_009_1174_1
crossref_primary_10_1016_j_remnie_2013_07_027
crossref_primary_10_1186_1479_7364_4_3_170
crossref_primary_10_1002_ana_21451
crossref_primary_10_1016_j_neubiorev_2010_08_009
crossref_primary_10_1212_01_wnl_0000261919_22630_ea
crossref_primary_10_1212_01_wnl_0000260969_94695_56
crossref_primary_10_1212_01_wnl_0000259035_98480_ed
crossref_primary_10_1097_RCT_0000000000000123
crossref_primary_10_1016_j_neurobiolaging_2007_03_029
crossref_primary_10_1038_mp_2008_115
crossref_primary_10_1016_j_nbd_2014_05_001
crossref_primary_10_3233_JAD_150190
crossref_primary_10_1007_s00401_013_1185_7
crossref_primary_10_1007_s11307_013_0625_z
crossref_primary_10_1016_j_neurobiolaging_2013_08_025
crossref_primary_10_2967_jnumed_108_051946
crossref_primary_10_1159_000530688
crossref_primary_10_1038_s41598_017_16236_1
crossref_primary_10_1016_j_nucmedbio_2012_03_001
crossref_primary_10_1007_s11682_011_9136_1
crossref_primary_10_1212_WNL_0b013e3181bacf1b
crossref_primary_10_1007_s12149_018_1236_1
crossref_primary_10_1186_s13195_020_00642_1
crossref_primary_10_2217_fnl_12_39
crossref_primary_10_1016_j_pharma_2008_11_004
crossref_primary_10_1007_s10072_019_03840_4
crossref_primary_10_1159_000506124
crossref_primary_10_1212_WNL_0b013e31821cccad
crossref_primary_10_1007_s13167_010_0036_z
crossref_primary_10_1016_j_mednuc_2011_02_007
crossref_primary_10_2217_14796708_4_1_23
crossref_primary_10_1016_j_npg_2009_06_001
crossref_primary_10_1016_j_jns_2010_11_012
crossref_primary_10_1016_j_neurobiolaging_2012_03_002
crossref_primary_10_1016_j_pscychresns_2008_07_015
crossref_primary_10_1002_mds_22581
crossref_primary_10_2217_fnl_10_23
crossref_primary_10_1093_brain_awn107
crossref_primary_10_3233_JAD_180645
crossref_primary_10_1007_s00415_012_6428_3
crossref_primary_10_1007_s12149_015_0957_7
crossref_primary_10_1007_s40336_014_0072_0
crossref_primary_10_1196_annals_1379_011
crossref_primary_10_3233_JAD_231013
crossref_primary_10_1002_ana_21212
crossref_primary_10_1021_acs_inorgchem_7b01883
crossref_primary_10_1148_radiol_2503080751
crossref_primary_10_1007_s00259_011_2051_2
crossref_primary_10_1016_j_brainresbull_2011_12_001
crossref_primary_10_1002_gps_4173
crossref_primary_10_1016_S1474_4422_08_70001_2
crossref_primary_10_1212_WNL_0b013e3181b23564
crossref_primary_10_12701_yujm_2018_35_1_1
crossref_primary_10_1016_j_neuroimage_2007_03_004
crossref_primary_10_2967_jnumed_114_153494
crossref_primary_10_1016_j_neuroimage_2008_02_035
crossref_primary_10_1007_s00259_009_1301_z
crossref_primary_10_1016_j_nicl_2014_02_001
crossref_primary_10_1117_1_JMI_4_2_024006
crossref_primary_10_6009_jjrt_2017_JSRT_73_4_298
crossref_primary_10_1186_s13550_019_0561_2
crossref_primary_10_1371_journal_pone_0084777
crossref_primary_10_1517_17530059_1_3_337
crossref_primary_10_3233_JAD_200840
crossref_primary_10_2967_jnumed_107_049932
crossref_primary_10_1007_s12603_009_0101_2
crossref_primary_10_1016_j_remn_2013_06_012
crossref_primary_10_1002_gps_1630
crossref_primary_10_1016_j_cpet_2009_12_003
crossref_primary_10_1016_j_neurobiolaging_2011_01_003
crossref_primary_10_1016_j_neuroimage_2008_07_022
crossref_primary_10_1097_MNM_0b013e32833019f3
crossref_primary_10_1007_s00259_007_0700_2
crossref_primary_10_1177_197140090802100603
crossref_primary_10_1007_s00259_011_1960_4
crossref_primary_10_1093_brain_awr044
crossref_primary_10_1093_braincomms_fcac016
crossref_primary_10_2967_jnumed_110_087031
crossref_primary_10_1016_j_neurol_2012_07_005
crossref_primary_10_1186_s13550_024_01181_8
crossref_primary_10_1007_s00259_008_0935_6
crossref_primary_10_1002_gps_4235
crossref_primary_10_1021_jm070025
crossref_primary_10_1016_j_neurobiolaging_2010_06_015
crossref_primary_10_3389_fphar_2016_00088
crossref_primary_10_1016_j_cger_2013_07_006
crossref_primary_10_1007_s00115_010_2951_6
crossref_primary_10_1038_nrneurol_2009_217
crossref_primary_10_2217_fnl_14_13
crossref_primary_10_1007_s00259_010_1382_8
crossref_primary_10_1093_brain_awv278
crossref_primary_10_1017_S0959259812000160
crossref_primary_10_1212_WNL_0b013e3181a2e896
crossref_primary_10_3389_fnhum_2017_00643
crossref_primary_10_1007_s00259_013_2350_x
crossref_primary_10_2967_jnumed_108_058529
crossref_primary_10_1016_j_arcmed_2012_11_009
crossref_primary_10_1016_j_parkreldis_2010_08_021
crossref_primary_10_1212_01_wnl_0000257671_88772_f1
crossref_primary_10_1212_01_wnl_0000265815_38958_b6
crossref_primary_10_4061_2011_481903
crossref_primary_10_1007_s12149_018_1258_8
crossref_primary_10_1111_ejn_12633
crossref_primary_10_1001_jamanetworkopen_2020_27472
crossref_primary_10_1007_s00259_013_2415_x
crossref_primary_10_1016_j_nbd_2008_10_003
crossref_primary_10_3390_cancers16010010
crossref_primary_10_1016_j_neuropsychologia_2017_04_002
crossref_primary_10_1016_S1474_4422_07_70178_3
crossref_primary_10_1259_bjr_97295129
crossref_primary_10_1007_s12149_020_01513_3
crossref_primary_10_1016_j_neuroscience_2010_03_044
crossref_primary_10_3233_JAD_170092
crossref_primary_10_1093_brain_awm336
crossref_primary_10_1093_brain_awp326
crossref_primary_10_3988_jcn_2009_5_4_153
crossref_primary_10_1002_ana_23797
crossref_primary_10_1093_gerona_glab130
crossref_primary_10_1016_j_neurobiolaging_2021_08_016
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1212/01.wnl.0000240117.55680.0a
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1526-632X
ExternalDocumentID 16971697
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
.XZ
.Z2
01R
0R~
123
1J1
1KJ
354
3PY
4Q1
4Q2
4Q3
53G
5RE
5VS
6PF
77Y
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAWTL
AAXQO
AAYEP
AAYOK
ABBLC
ABIVO
ABJNI
ABOCM
ABVCZ
ABXYN
ABZZY
ACCJW
ACDDN
ACGFS
ACIJW
ACILI
ACLDA
ACOAL
ACWRI
ACXJB
ACZKN
ADGGA
ADNKB
AE6
AEBDS
AENEX
AFDTB
AFEXH
AFFNX
AFNMH
AFUWQ
AGINI
AHOMT
AHQNM
AHQVU
AHVBC
AIJEX
AJCLO
AKCTQ
AKULP
AKWKN
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMKUR
AMNEI
AOHHW
BOYCO
BQLVK
BYPQX
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
E.X
EBS
ECM
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FW0
GQDEL
HZ~
H~9
IKYAY
IN~
J5H
JF7
KD2
KMI
L-C
L7B
N4W
N9A
NEJ
NPM
N~7
N~B
O9-
OAG
OAH
OBH
ODMTH
OHH
OHYEH
OL1
OLB
OLH
OLU
OLV
OLY
OLZ
OPX
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
RLZ
RXW
SJN
TEORI
V2I
VVN
W3M
WH7
WOQ
WOW
X7M
XJT
XOL
XSW
XXN
XYM
XYN
YBU
YCJ
YFH
ZKB
~9M
ID FETCH-LOGICAL-c451t-1d43dcbc7806247d75eda2c0808ee18b05836f8b1f3d80fc7f7485ee5d3f5d9e2
IngestDate Thu Apr 03 06:58:05 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c451t-1d43dcbc7806247d75eda2c0808ee18b05836f8b1f3d80fc7f7485ee5d3f5d9e2
PMID 16971697
ParticipantIDs pubmed_primary_16971697
PublicationCentury 2000
PublicationDate 2006-11-14
PublicationDateYYYYMMDD 2006-11-14
PublicationDate_xml – month: 11
  year: 2006
  text: 2006-11-14
  day: 14
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Neurology
PublicationTitleAlternate Neurology
PublicationYear 2006
SSID ssj0015279
Score 2.3299315
Snippet PET studies with N-methyl-[(11)C]2-(4':-methylaminophenyl)-6-hydroxybenzothiazole ([(11)C]PIB) have revealed an increased tracer uptake in several brain...
SourceID pubmed
SourceType Index Database
StartPage 1575
SubjectTerms Aged
Aged, 80 and over
Alzheimer Disease - diagnostic imaging
Alzheimer Disease - metabolism
Alzheimer Disease - physiopathology
Amyloid beta-Peptides - metabolism
Benzothiazoles - pharmacokinetics
Brain - diagnostic imaging
Brain - metabolism
Brain - physiopathology
Brain Mapping - methods
Carbon Radioisotopes
Cerebral Cortex - diagnostic imaging
Cerebral Cortex - metabolism
Cerebral Cortex - physiopathology
Corpus Striatum - diagnostic imaging
Corpus Striatum - metabolism
Corpus Striatum - physiopathology
Female
Humans
Image Processing, Computer-Assisted - methods
Ligands
Male
Middle Aged
Positron-Emission Tomography - methods
Predictive Value of Tests
Up-Regulation - physiology
Title Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease
URI https://www.ncbi.nlm.nih.gov/pubmed/16971697
Volume 67
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELYoSIgL4v1GPtDTykscP-Ict6WopWrpYYsqIVQ5sV0Wstmo2grUX8_4sZtloQi4WFGsWJbny9gznvkGoVeOZ06V3BLL64pwW1JSMmGIYFJlhpdZbrxD_-BQ7h7zdyfipA8rCtkl82pYX_42r-R_pArvQK4-S_YfJLscFF7AM8gXWpAwtH8l4w-z77YhfiPyhKs9u8jRznigp2CKT8ygmZx53_im2KJ0e1O8OdrbGlx0c_01sIWMmsvPdjL1ZcJXbmq-LCidLs5_8rrv22nXaTiXxiSt3pM60k0ox9Q7UnsayL3eXXoYruXF2XkcYH_N5eDD3qLZb5OazCWRLBRCX-rRWFYj4aVcUYpUxOIov2hr2DZDBsLwW9sEIkk4XlBaDD0rWjbM9OpHsPLdNMiRSk97FaN6_9y7xqS96NpAG2BT-CKp3rOTbpxEXpSJlBam9frqSXma2TTQmikSjiTjO-h2siXwKALjLrpm23vo5kGKlriP3q_gAy_wgWcOAz5wwgeO-MAfAR2fABs4YgNPWrzEBk7YeICO3-6Mt3dJKqBBai7onFDDmamrulCZzHlhCmGNzj23vLKWqioTikmnKuqYUZmrC1dwJawVhjlhSps_RNfbWWsfI6ydDzbOqTYl4zmVylaaOQ7GrpA1Y-IJehSX4rSLLCmni0V6emXPM3SrR9dzdMPBb2lfwBlvXr0MwvkBrWZIkw
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Voxel-based+analysis+of+PET+amyloid+ligand+%5B11C%5DPIB+uptake+in+Alzheimer+disease&rft.jtitle=Neurology&rft.au=Kemppainen%2C+N+M&rft.au=Aalto%2C+S&rft.au=Wilson%2C+I+A&rft.au=N%C3%A5gren%2C+K&rft.date=2006-11-14&rft.eissn=1526-632X&rft.volume=67&rft.issue=9&rft.spage=1575&rft_id=info:doi/10.1212%2F01.wnl.0000240117.55680.0a&rft_id=info%3Apmid%2F16971697&rft_id=info%3Apmid%2F16971697&rft.externalDocID=16971697